Crinetics Pharmaceuticals (CRNX) executive Pizzuti sold 30,000 shares for $913K at $30.43 under a 10b5-1 plan

Insider transactions reported

Dana Pizzuti (Chief Med and Dev Officer at Crinetics Pharmaceuticals Inc., CRNX) reported that they sold 30,000 shares for $913K at $30.43, and acquired 30,000 shares at $16.89 on Aug 22, 2025. After these transactions the filing shows 66,270 shares held directly.

Reporting person

Pizzuti Dana

Role

Chief Med and Dev Officer

Options and other derivatives

Holdings before and after

• Stock Option (Right to Buy): 119,042 to 89,042 direct

Footnotes from the filing

1. 1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
2. 2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $30.43 per share. The range of sales prices on the transaction date was $30.00 to $30.98 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
3. 3. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Transaction codes in this filing

Open-market sale:

Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

Exercise or conversion of a derivative:

Code M marks the exercise or conversion of an option or other derivative under an exempt plan.

FAQ